Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep-Oct;31(5):e564-e566.
doi: 10.1097/MJT.0000000000001713. Epub 2024 Jul 11.

Continuous Infusion of Turoctocog Alfa in Patients With Mild to Moderate Hemophilia A: A Case Series

Megan Wayman  1 , Loan Nguyen  2 , Donald C Moore  1 , Mary Ann Knovich  3 , Justin Arnall  4
Affiliations
Case Reports

Continuous Infusion of Turoctocog Alfa in Patients With Mild to Moderate Hemophilia A: A Case Series

Megan Wayman et al. Am J Ther. 2024 Sep-Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

M. Wayman, L. Nguyen, D. C. Moore, and M. A. Knovich: These authors have no conflicts of interest to declare. J. Arnall has been a member of a CTI BioPharma and HEMA Pharmaceutical Advisory Board and previously spoke for the Novo Nordisk (Hemophilia) Speaker's Bureau.

References

    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–e47.
    1. NovoEight [package Insert]. Plainsboro, NJ; Novo Nordisk Inc; 2018.
    1. Takeyama M, Nogami K, Kobayashi R, et al. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report. Int J Hematol. 2018;108:199–202.
    1. Takeyama M, Nøhr AM, Pollard D. Stability of turoctocog alfa, a recombinant factor VIII product, during continuous infusion in vitro. TH Open. 2020;4:e354–e361.
    1. Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19:691–697.

LinkOut - more resources